Claudin 18.2 mRNA

Description

Ready-to-use Claudin 18.2 mRNA

For in vitro mRNA transfection and in vivo mRNA delivery by injection

Encodes the tight junction protein Claudin 18.2, is a specific biomarker for gastric cancer, pancreatic cancer, and other gastrointestinal malignancies, which is widely used in the development of CAR-T cell therapies and antibody-drug conjugates (ADCs) –  for research and development in the context of cancer research, anti-Claudin 18.2 targeted therapy, and mRNA vaccine development.

Manufactured by Levostar´s monoPlasmid technology

Designed for optimal expression results:

• Enhanced polyA(+) Stability – for preventing RNA degradation

• Cap1 Structure – for optimal ribosome recruiting

• Carefully selected UTR Regions – to enhance translation initiation

N1-Methylpseudouridine Modification

For enhanced mRNA stability and decreased anti-mRNA immune response Levostar´s catalog mRNAs are in vitro transcribed using N1-Methylpseudouridine (N1-Me-Ψ, N1mpU) by default. If you prefer unmodified mRNA or you require a different modification, please contact us.

Quality Standards: Tested for high purity, low endotoxin,  low residual dsRNA & plasmid template DNA, high capping efficiency, and proper polyA(+)-length.

Contents:  1 mg mRNA, lyophilized          – also available in solution (1 mg/ml), please inquire

Shipping and Storage:   Lyophilized mRNA shipped at room temperature (≤ 25°C). Store at –80°C upon dissolving.

For other mRNA quantities than 1 mg including bulk offers please contact us for pricing

mRNA may also be ordered already encapsulated in Lipid Nanoparticles for high efficiency mRNA delivery – please contact us for a quotation.

For mRNA encapsulation in your lab and subsequent in vitro mRNA transfection or in vivo mRNA delivery we offer Levostar´s portfolio of NeoLNP Kits.